Masoud Azodi

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller et al. · The Lancet Oncology · 2019 · 516 citations

Oncology, Metronomic Therapy, Gynecology +6

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

Amanda N. Fader, Dana M. Roque, Eric R. Siegel et al. · Journal of Clinical Oncology · 2018 · 509 citations · Full text

Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer

Timothy R. Rebbeck, Nandita Mitra, Fei Wan et al. · JAMA · 2015 · 484 citations · Full text

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

Siming Zhao, Murim Choi, John D. Overton et al. · Proceedings of the National Academy of Sciences · 2013 · 333 citations · Full text

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

Amanda N. Fader, Dana M. Roque, Eric R. Siegel et al. · Clinical Cancer Research · 2020 · 292 citations · Full text